|
Tucson,
AZ, and Hayward, CA . September 7th, 2004
Ventana Medical Systems, Inc. (Nasdaq: VMSI), and
Quantum Dot Corporation (QDC) announced comprehensive
licensing and supply agreements relating to QDC’s
Qdot® nanocrystal technology for in vitro diagnostic
applications in Anatomic Pathology and Cytology. Ventana
will also incorporate QDC technology in its research
and pharmaceutical discovery platforms. Under the
terms of the agreement, QDC will supply Qdot nanocrystals
for Ventana’s incorporation into next-generation rapid,
quantitative, and multiplexed assays for cancer diagnosis
and disease management. Financial terms of the agreement
were not disclosed.
”As a leading
provider of automated diagnostic solutions, Ventana
is committed to identifying those technologies that
enable us to effectively address the increasing demands
placed on the anatomical pathology laboratory in the
important role they play in improving patient care,”
stated Christopher Gleeson, President and Chief Executive
Officer of Ventana. “Quantum Dot’s expertise and intellectual
property provide tools for Ventana to extend our leadership
position in tissue-based molecular diagnostics, and
we look forward to a very productive partnership.”
”The choice of our
Qdot nanocrystals for Ventana’s expansion into fluorescent
in vitro diagnostics continues to validate the value
of our technology,” commented George Dunbar, QDC’s
Chief Executive Officer. “Leveraging Ventana’s development
expertise and worldwide sales and distribution capabilities
is an effective way to provide Qdot nanocrystal products
to anatomic pathology customers. This is a good model
for future field-defined partnerships for our company.”
About Ventana Medical
Systems, Inc.
Ventana develops,
manufactures, and markets instrument/reagent systems
that automate slide preparation and staining in clinical
histology and drug discovery laboratories worldwide.
Ventana’s clinical systems are important tools used
in the diagnosis and treatment of cancer and infectious
diseases. Ventana’s drug discovery systems are used
to accelerate the discovery of new drug targets and
evaluate the safety of new drug compounds.
About Quantum Dot
Corporation (www.qdots.com)
Quantum Dot is a privately
held bioscience company that has pioneered the development
and commercialization of Qdot® nanocrystals for
bio-detection in discovery and clinical applications.
QDC’s current products include more than 40 life science
kits and applications, used by life science discovery
laboratories worldwide. QDC will soon be launching
its first integrated instrumentation, software, and
bio-reagents platform, the Mosaic™ system, for rapid
and quantitative multiplexed gene expression analysis.
QDC collaborates with leading academic and industrial
partners and has over 130 patents and patents-pending.
Any
statements made about the Ventana’s anticipated success
of product development activities and product development
are forward-looking statements subject to risks and
uncertainties, such as the risks inherent in the development,
manufacturing, marketing and sale of medical products,
competitive factors, general economic conditions,
legal disputes, and government actions as more fully
described in Ventana’s Annual Report on Form 10-K
for the year ended December 31, 2003. Actual results
may differ materially from anticipated results.
Ventana Medical Systems Contacts:
Christopher M. Gleeson
President and CEO
(520) 229-3787
Nick Malden
Chief Financial Officer
(520) 229-3857
Quantum Dot Corporation
Contacts:
George Dunbar
CEO
(510) 887-8775
Carol Lou
President
(510) 887-8775
Copyright Ventana
Medical Systems and Quantum Dot Corporation. Reprinted
with permission.
If you have a comment,
please email us.
|
